Arthrobacter globiformis

Synopsis

Arthrobacter globiformis: A Comprehensive Reference on Identity, Biology, and Use as a Dietary Supplement Ingredient

1. Identity and Taxonomy

1.1 Scientific Classification

Arthrobacter globiformis is a Gram-stain-positive, obligately aerobic, chemoorganotrophic species of bacteria in the genus Arthrobacter, belonging to the family Micrococcaceae within the phylum Actinomycetota. Under the classification scheme of Bergey's Manual of Systematic Bacteriology (2011), both Arthrobacter and the closely related Micrococcus are placed in the class Actinobacteria, Subclass V: Actinobacteridae, Order I: Actinomycetales, Suborder IX: Micrococcineae, Family I: Micrococcaceae.

The full taxonomic lineage, as recorded in the NCBI Taxonomy Browser, is: cellular organisms → Bacteria → Bacillati → Actinomycetota → Actinomycetes → Micrococcales → Micrococcaceae → Arthrobacter.

1.2 Nomenclatural History

Arthrobacter globiformis was first discovered by H. J. Conn in 1928. The species traversed several nomenclatural revisions: originally described as Bacterium globiforme (Conn, 1928), it was reclassified as Achromobacter globiformis (Bergey et al., 1930) before receiving its current binomial name Arthrobacter globiformis (Conn and Dimmick, 1947). First described in 1928 from soil samples and formally named in 1947, A. globiformis serves as the type species of the genus Arthrobacter.

The type strain is deposited under multiple culture collection accession numbers, including ATCC 8010, DSM 20124, and numerous others across international repositories.

1.3 Morphology and Pleomorphism

A. globiformis is distinguished by its pleomorphic morphology, exhibiting a characteristic rod–coccus growth cycle where young cells appear as irregular rods that transition to coccoid forms in stationary phase, often forming V-shaped arrangements due to snapping division. In 24-hour agar slant cultures, A. globiformis appears as short rods, 0.6–0.5 × 1.0–1.5 µm in size. After 3–4 days, the cultures show Gram-positive cocci, 0.8–1.2 µm in diameter, which occur in pairs and tetrads.

The species is non-motile or motile by flagella in some strains, catalase-positive, non-spore-forming, and has a DNA G+C content of approximately 66 mol%, with peptidoglycan type A3α containing L-lysine as the diamino acid and major menaquinones MK-9(H₂). Their cell walls contain polysaccharides (with monomers glucose, galactose, and rhamnose), peptidoglycan, and phosphorus.

1.4 Genome

The complete genome of A. globiformis has been sequenced using whole-genome shotgun sequencing. The genomes of three strains are available for public use. The genome is approximately 4.89 million base pairs long, containing 4,305 proteins and a 66.1% GC content. Genome analysis of soil isolates revealed many genes encoding stress-related proteins.

1.5 Natural Habitat and Ecological Distribution

A. globiformis was initially found in large quantities in various types of soil. A. globiformis is nutritionally versatile and reported to be ubiquitous in freshwater, saltwater, and soils. Because of their nutritional versatility, arthrobacters are commonly isolated from soil, sewage, food, and various other environmental samples using nonselective and simple media such as Plate Count Agar.

Individual strains have been found in diverse niches: one strain, designated A. globiformis mrc11, was isolated from a Khangkhui cave deposit in the Ukhrul district of Manipur, India, at 1,652 m above sea level. An additional strain was isolated from a ginseng field in Iljuk, Anseong, Korea.

2. Natural Sources and Forms of Commercial Preparation

2.1 Primary Source

Arthrobacter globiformis is a soil microorganism that can have the ability to act as a probiotic in the human body. As a dietary supplement ingredient, it is classified within the emerging category of soil-based organisms (SBOs) — bacteria isolated from terrestrial environments rather than from traditional fermentation or dairy processes.

2.2 Supplement Forms and Preparations

In the context of human supplementation, A. globiformis has been incorporated into multi-strain, soil-based probiotic formulations. The most documented of these is the commercial product Prescript-Assist, which contains 29 soil-based microorganisms (SBOs) as the probiotic component. The listed strains include Arthrobacter agilis, Arthrobacter citreus, Arthrobacter globiformis, Arthrobacter luteus, Arthrobacter simplex, as well as species such as Bacillus subtilis, Azotobacter spp., and several others. The prebiotic component of this formulation is largely leonardite, a nutritional medium that enhances SBO proliferation.

The inclusion of Arthrobacter globiformis in nutritional products is a more recent development, driven by emerging interest in beneficial bacteria beyond the well-known probiotics such as Lactobacillus and Bifidobacterium.

Researchers have also investigated incorporating isolated A. globiformis bacteria into functional food vehicles. A probiotic chocolate preparation has been formulated by combining chocolate, flaxseed powder, and Arthrobacter globiformis. This type of product remains at a research stage and is not an established commercial form.

The characteristics of Arthrobacter globiformis strain ATCC 8010 make it suitable for use in various applications including food production, biocontrol, probiotic use in humans and animals, biodegradation, and water and wastewater treatment.

3. Traditional and Historical Use

Historically, Arthrobacter globiformis has not been a traditional herb or remedy in ancient medicinal systems; it has played an indirect role in promoting human health through its natural presence in fermented products and soil-enhanced botanicals.

There is no documented evidence from historical pharmacopoeias, traditional medicine systems (Ayurveda, Traditional Chinese Medicine, Indigenous American medicine, European herbalism, or other formalized traditions), or pre-modern texts referencing the deliberate use of Arthrobacter globiformis as a therapeutic agent. The bacterium was not described or classified as a species until 1928, and its potential for human probiotic application was not explored until much later in the 20th century.

Early adopters of soil-based organism (SBO) therapies recognized the value of this bacterium in fostering a resilient microbiome. As research evolved, its significance grew among practitioners of alternative wellness, who incorporated A. globiformis as part of broader probiotic and soil-based supplement regimens. This usage context is modern — originating in the late 20th and early 21st centuries — and is not rooted in any codified traditional medicine system.

4. Key Constituents and Active Compounds

4.1 Choline Oxidase (CodA)

The most extensively characterized enzymatic constituent of A. globiformis relevant to potential health applications is choline oxidase. Choline oxidase was first described in 1977 by Ikuta et al., who reported the purification and initial characterization of the enzyme from the soil bacterium Arthrobacter globiformis. Choline oxidase is found in A. globiformis. It is a cytosolic flavoprotein, hydrogen-peroxide-forming oxidase that oxidizes choline to produce glycine betaine by a two-step reaction with betaine aldehyde as the intermediate.

Choline oxidase catalyzes the four-electron, two-step, flavin-mediated oxidation of choline to glycine betaine. The enzyme is important both for medical and biotechnological reasons, because glycine betaine is one among a limited number of compatible solutes used by cells to counteract osmotic pressure.

The codA gene encoding for choline oxidase has been cloned from the genomic DNA of A. globiformis strain ATCC 8010 and expressed to high yields in Escherichia coli. Mechanistic, structural, and computational studies have elucidated the mechanism of action of the enzyme from A. globiformis at the molecular level.

4.2 Inulinase

Arthrobacter globiformis produces an inulinase, which degrades inulin through an exo-type reaction. Inulin is a well-established prebiotic dietary fiber found in many plant foods; enzymatic degradation of inulin produces fructooligosaccharides and fructose monomers. The relevance of this enzyme to probiotic functionality in the gut has been noted in the scientific literature but remains largely biochemically characterized rather than clinically demonstrated for A. globiformis specifically.

4.3 Trehalose and Glycogen

Cells of A. globiformis grown in carbohydrate-rich media were found to contain large quantities of low-molecular-weight carbohydrates (800 µg/mg protein) and high amounts of glycogen (2 mg/mg protein). At increasing osmotic values of the medium, low-molecular-weight carbohydrate levels increased to 1,300 µg/mg protein. These low-molecular-weight carbohydrates consist mainly of α,α-trehalose.

Levels of trehalose in Arthrobacter cells tend to remain constant during nutrient exhaustion, while glycogen is consumed. The stress-tolerant properties of Arthrobacter — including resistance to nutrient starvation, desiccation, and high salt concentration — are linked to the high glycogen and trehalose contents of the cells.

4.4 Levoglucosan Dehydrogenase and Related Carbohydrate-Active Enzymes

Arthrobacters, especially those isolated from soil, have enzymes that enable them to degrade unusual and polymeric compounds. Strains that use levoglucosan (1,6-anhydro-β-D-glucopyranose) possess a levoglucosan dehydrogenase. Glucose is produced from levoglucosan by three steps: dehydrogenation, intramolecular hydrolysis, and NAD-dependent reduction. Levoglucosan dehydrogenase catalyzes the initial step.

Arthrobacter globiformis grows on glycine as the sole carbon and energy source and converts this amino acid through serine into pyruvate.

4.5 Cell Wall Constituents

The cell walls of A. globiformis contain polysaccharides (with monomers glucose, galactose, and rhamnose), peptidoglycan, and phosphorus. Cell wall polysaccharides and glycolipids represent structural components that may interact with mammalian immune receptors; glycolipid structural characterization has been published for both A. globiformis and related species.

4.6 Secondary Metabolites with Antimicrobial Activity

One strain, A. globiformis mrc11, was isolated from a Khangkhui cave deposit and shown to have antimicrobial properties. Its draft genome has a genome size of 4.89 Mb, a 65.9% GC content, and 4,657 predicted open reading frames. Analysis of the genome was initiated to gain insights into the mechanisms of this antimicrobial activity. The strain was found to harbor important putative secondary metabolites and antibiotic biosynthesis genes, with further exploration anticipated to yield clinically significant compounds.

5. Proposed Mechanisms of Action Relevant to Supplemental Use

5.1 Enzymatic Degradation of Complex Substrates

The enzymatic profile of A. globiformis is one of the central rationales for its inclusion in soil-based probiotic formulations. Its inclusion in nutritional supplements is rooted in its unique enzymatic capabilities, particularly its ability to break down complex organic compounds, thus aiding digestion and nutrient absorption. Specifically, the organism's inulinase activity and demonstrated capacity to metabolize polysaccharides are considered relevant to intestinal prebiotic metabolism, though no peer-reviewed clinical data directly demonstrate these mechanisms operating in the human gastrointestinal tract at doses currently formulated in supplements.

5.2 Osmotic Stress Tolerance and Gastrointestinal Survival

For any probiotic organism to confer benefit, it must first survive conditions in the upper gastrointestinal tract. Laboratory data demonstrate that A. globiformis pH tolerance was studied with pH levels of 3, 4, 5, and 6 for 1, 2, and 3 hours, with the organism showing growth at all pH levels in the given time interval. Tolerance towards bile salt was demonstrated at concentrations of 0.5%, 1%, and 3% of bile. These in vitro observations suggest a degree of acid and bile resistance, but they have not been validated in controlled in vivo human studies.

The underlying biochemical basis for this stress tolerance is related to intracellular accumulation of protective compatible solutes: betaine acts as a nontoxic osmolyte, highly compatible with metabolic functions at high cytoplasmic concentrations, and contributes to turgor adjustment in cells subjected to osmotic stress.

5.3 Immune Modulation

In vitro cytotoxicity and immune activation testing were conducted as part of the Canadian Government's formal risk assessment of A. globiformis strain ATCC 8010. A. globiformis strain ATCC 8010 was not toxic to HT29 human colonic epithelial cells or J774A.1 mouse macrophage cells upon 48-hour exposure, and no significant activation of pro-inflammatory cytokines was observed. These in vitro results indicate a low inflammatory potential, though they do not constitute clinical efficacy data for immune support.

5.4 Antimicrobial Competition

The ability of A. globiformis to suppress other bacteria has been reported. For example, A. globiformis is used as a probiotic in shrimps for its ability to inhibit infection with pathogenic Vibrio harveyi, both in vitro and in vivo. Whether analogous competitive exclusion mechanisms operate in the human gut has not been established in peer-reviewed clinical research.

6. Scientific Evidence by Area of Use

6.1 Gastrointestinal Health and Irritable Bowel Syndrome (IBS)

The most directly relevant clinical evidence for A. globiformis as a supplement component comes from studies on the multi-strain SBO product Prescript-Assist, which lists A. globiformis as one of its constituent organisms. It must be stressed that this evidence pertains to the composite formulation, not to A. globiformis alone.

A randomized, placebo-controlled, double-blind clinical study was published in Clinical Therapeutics (2005, Vol. 27, No. 6, pp. 755–761). Prescript-Assist is described as a probiotic–prebiotic complex with apparent efficacy for a wide range of gastrointestinal and other disorders, with the probiotic component including 29 soil-based microorganisms. In the methodologically oriented double-blind study in patients with IBS, combined probiotic–prebiotic treatment with Prescript-Assist was associated with significant reductions in IBS symptoms. A subsequent open-label, partially controlled, 1-year extension of the initial trial was published as: Bittner, Croffut, Stranahan, and Yokelson. "Prescript-Assist probiotic–prebiotic treatment for irritable bowel syndrome: an open-label, partially controlled, 1-year extension of a previously published controlled clinical trial." Clin Ther 29, 1153–1160 (2007).

Evidence quality: Both studies are limited by their evaluation of a complex multi-organism product. No study has isolated the contribution of A. globiformis specifically. The 2005 study was short (2 weeks) and evaluated a multi-strain formulation. No independent replication by separate research groups has been published to date. The evidence is therefore preliminary and cannot be attributed specifically to A. globiformis.

6.2 Aquaculture and Animal Probiotic Use

A study referenced by the Canadian government's formal assessment examined Arthrobacter species in animal models: a 2013 study examined the effect of dietary probiotic bacteria Arthrobacter species, β-1,3 glucan, and Moringa oleifera leaf on protection of Penaeus indicus juveniles from pathogenic Vibrio harveyi, published in Researcher, volume 5, pages 24–31. Animal and aquaculture data cannot be directly extrapolated to human clinical outcomes.

6.3 Enzyme Production and Biotechnology (Industrial Application)

A. globiformis and its antigens and proteins are commercially available for use in research, food production, biodegradation, and water/wastewater treatment. The most scientifically robust body of literature on A. globiformis concerns its choline oxidase enzyme, which has been extensively characterized in academic biochemistry. Choline oxidase catalyzes the oxidation of choline to glycine betaine via betaine aldehyde in glycine betaine biosynthesis, and betaine acts as an osmolyte. Choline oxidase has attracted great attention because of its wide application in clinical diagnostics and its potential use in enzymatic betaine production. The clinical diagnostic application refers to the use of choline oxidase in enzymatic assay kits, not to therapeutic supplementation.

6.4 Bioremediation (Environmental Application)

A novel strain, A. globiformis DC-1, isolated from DDT-contaminated soil, demonstrates the ability to degrade DDT as its sole carbon and energy source, achieving up to 70% degradation within 7 days under optimal conditions, highlighting its potential for remediating pesticide residues in contaminated environments. Similarly, chromium-resistant strains like A. globiformis 151B exhibit bioremediation potential by reducing hexavalent chromium (Cr(VI)) in wastewater. These findings have no direct human health supplementation relevance but illustrate the organism's broad metabolic capabilities.

7. Body Systems Associated with Arthrobacter globiformis in Supplement Contexts

Gastrointestinal system: The primary rationale for its use as a supplement is support of gut microbiome diversity and digestive enzyme activity. Evidence is limited to a small number of multi-strain product studies.
Immune system: Preliminary studies have shown that certain strains of Arthrobacter can produce bioactive compounds, including antioxidants and enzymes that may support metabolic and digestive health. No human clinical trials have demonstrated immunological effects specifically attributable to A. globiformis.
Metabolic system: The organism's choline oxidase activity and involvement in choline–betaine metabolism are relevant biochemical connections to broader metabolic function, but no human metabolic outcome studies have been conducted.

Overall, scientific validation for the health benefits of Arthrobacter globiformis is still in its early stages.

8. Dosage Forms and Reported Dosages

Arthrobacter globiformis is not formulated or studied as a single-organism supplement in peer-reviewed human clinical trials. Its supplemental use appears exclusively within multi-strain SBO formulations. The only published human dosing information available from verifiable sources pertains to multi-strain products in which A. globiformis is one of many constituents:

One commercial multi-strain SBO product (Prescript-Assist) contains the organism within a proprietary blend, with a suggested adult use of 1–2 capsules per day.
Another reported dosing protocol for a similar soil-based probiotic product is 2 capsules per day for the first 30 days, followed by 1 to 2 capsules per week thereafter.

No peer-reviewed clinical research has defined a specific dose, colony-forming-unit (CFU) count, or therapeutic window for A. globiformis as a standalone supplement ingredient. The organism's contribution to total CFU load in multi-strain formulations is not reported separately in available published studies.

9. Safety Considerations

9.1 Government Regulatory Assessment

The Government of Canada conducted a formal, science-based screening assessment of A. globiformis strain ATCC 8010 under the Canadian Environmental Protection Act, 1999. The strain was estimated to have a low hazard toward both human health and the environment; it is concluded that Arthrobacter globiformis strain ATCC 8010 is not harmful to human health or to the environment.

Despite its widespread distribution and a history of use in aquatic invertebrates as a probiotic and in plants as a biocontrol agent, A. globiformis strain ATCC 8010 has not been implicated in infections or other adverse effects in terrestrial and aquatic plants, vertebrates, or invertebrates. Considering all information presented in this assessment, the risk to human health from A. globiformis strain ATCC 8010 is low.

9.2 Absence of Reported Human Infections with A. globiformis

There are no known instances of human infection with A. globiformis or any of its synonyms. In the unlikely event of infection, clinically relevant antibiotics are available.

9.3 Infections Attributed to Other Arthrobacter Species

While A. globiformis itself has not been implicated in human infections, related species in the same genus warrant contextual note. Cases of human infection have been attributed to other Arthrobacter species. However, these cases are rare and occurred in immunocompromised individuals. Certain other Arthrobacter species have been implicated in opportunistic human infections predominantly in immunocompromised individuals and those with underlying medical conditions. Infections reported include bacteremia, postoperative endophthalmitis, Whipple's disease-like syndrome, phlebitis, endocarditis, and catheter-related blood and urinary tract infections. The majority of Arthrobacter infections are attributed to A. cumminsii, A. oxydans, and A. aurescens.

9.4 Antibiotic Susceptibility Profile

Arthrobacter globiformis strain ATCC 8010 is susceptible to clinically relevant antibiotics in the unlikely event of infection. More specifically, A. globiformis was reported to be susceptible to erythromycin, gentamicin, imipenem, meropenem, penicillin, rifampin, tetracycline, and vancomycin. A. globiformis was found to be resistant to sulfonamides.

9.5 Occupational Exposure and Allergy Risk

One report from Poland documents occupational exposure to barley and barley dust containing A. globiformis, along with other bacteria, being associated with extrinsic allergic alveolitis (hypersensitivity pneumonitis) among agricultural workers. The specific contribution of A. globiformis to the reaction was not elucidated. This finding concerns inhalation exposure in an agricultural occupational context, not oral supplementation.

9.6 In Vitro Cytotoxicity Data

The Canadian screening assessment included formal in vitro testing: in vitro cytotoxicity testing was performed using bioreduction activity of mouse macrophage cells (J774A.1) and human colon epithelial cells (HT29) upon exposure to A. globiformis strain ATCC 8010 and the positive control LPS (lipopolysaccharide) for 4 hours and 24 hours, with or without gentamycin treatment. The strain was not toxic to either cell type, and no significant activation of pro-inflammatory cytokines was observed.

9.7 Absence of Specific Drug Interaction Data

No peer-reviewed clinical pharmacology studies examining drug–A. globiformis interactions have been identified in the literature. Standard precautions applicable to probiotic supplementation in general — particularly in individuals taking immunosuppressant medications or with severely compromised immune systems — are discussed in the broader probiotic safety literature, but no interaction data specific to A. globiformis are available from verifiable sources.

10. Summary of Evidence Status

Arthrobacter globiformis has a well-established and extensively studied biochemistry in the scientific literature — particularly in relation to its choline oxidase enzyme, stress tolerance mechanisms, and biodegradative capabilities. However, as a dietary supplement or probiotic ingredient specifically intended for human therapeutic benefit, the evidence base is very limited. The available clinical evidence comes from a small number of studies on multi-strain SBO products (Prescript-Assist) in which A. globiformis is one of many co-administered organisms; no published clinical trial has isolated its individual contribution to any human health outcome.

Regulatory assessment by Health Canada has characterized the organism as low hazard to human health at current exposure levels, and no human infections with A. globiformis specifically have been reported in the scientific or medical literature. The field remains in early, predominantly preclinical and in vitro stages with respect to supplement-specific claims.